Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

and AstraZeneca is hoping to change that. At ASCO, AZ reported the full data from its DUO-O study of PD-L1 inhibitor Imfinzi (durvalumab) as a combination regimen with its PARP inhibitor Lynparza ...

AstraZeneca has upped its revenue expectations ... The company’s cancer immunotherapy Imfinzi (durvalumab) is also shaping up to become a billion dollar a year drug as countries outside the ...

AstraZenecas drug Imfinzi (NASDAQ: AZN) has received U.S. approval to treat adult patients with muscle-invasive bladder cancer, a significant advancement in cancer therapy. The approval allows ...